Ps1093 in Elderly Patients With Newly Diagnosed Dlbcl, Change Weight After the First Course R-Chop (-Like) Chemotherapy Is an Adverse Prognostic Factor

Abstract

We have evaluated the peripheral blood progenitors harvest. Nineteen patients started stem cell mobilization, one failed mobilization (5%) and 18 patients mobilized (95%). Nine out 18 patients did not reinfuse and 9 reinfused: 7 (24%), after a median follow up of 24 months, are alive and without evidence of disease, 1 was in partial remission and 1 progressed immediately after transplant. The overall survival and progression free survival are reported in Figures 1 and 2. Sixteen patients (89%) mobilized after 1 or 2 apheresis and the other two patients after three or four. The mean number of CD34+ cells mobilized was 5.8, the median number was 5.5 (IQR: 5 -6.75). The mean number of reinfused CD34+ cells in the 9 patients was 4.1, the median number was 4.1 (IQR: 3.5 -5). Summary/Conclusion: The association of Obinutuzumab and DHAP did not pass the interim analysis because a lower rate of CMR reported in comparison with the hypothesis. To note that seven patients (4 refractory and 3 relapsed) among the nine transplanted are alive and free from disease after a median follow-up of 24 months. Obinutuzuamb associated with a standard mobilizing chemotherapy (DHAP) did not compromise stem cell mobilization and engraftment after ASCT in this group of DLBCL patients.